surrounding structures. The wound is closed with a series of purse string 2-0 Maxon sutures.
INTRODUCTION AND OBJECTIVES: Castration-resistant prostate cancer (CRPC) emerges after androgen deprivation therapy and remains incurable due to the lack of effective therapies. Treatment with new generation androgen receptor (AR) antagonist Enzalutamide (ENZU) offers an initial response followed by drug resistance and the patient clinically progresses on this agent. Thus increased understanding of the target(s) of CRPC resistance may lead to the development of novel therapeutic approaches. Enhancer of zeste homolog 2 (EZH2), a member of functional enzymatic component of the Polycomb Repressive Complex 2, is an important target in CRPC whose oncogenic activity increases during castration and is polycomb independent. EZH2 also acts as a co-activator of AR mediating gene suppression, potentially causing ENZU resistance. We hypothesize that dual targeting of AR and EZH2 could significantly inhibit proliferation and migration ability of CRPC cells.
METHODS: Human prostate cancer C4-2B and 22Rv1 cells were treated with AR antagonist ENZU and EZH2 inhibitor GSK126 individually and in combination, followed by assessment of cell viability, cell cycle analysis, migration, invasion and expression of various target genes by Western blotting. ELISA was employed to assess the change in activity of histone methylation in these cells.
RESULTS: Treatment of C4-2B and 22Rv1 cells individually with ENZU and GSK126 (2.5-80µM) for 24 h exhibited a partial suppressive effect in cell growth. Using GSK126 and ENZU combination at 1:1, 1:5, 1:10 and 1:20 micro-molar ratio exhibited increased cell growth inhibition, where 1:10 ratio showed maximum efficacy in inhibiting cell growth in both cell lines. This combination caused marked increase in G1-phase cell cycle arrest, inhibition of migration and invasion, and reduction in H3K27 trimethylation in both cell lines. Strikingly, RWPE1, a human transformed prostate epithelial cells, exhibited minimal growth inhibitory effects in combination at highest ratio. Furthermore, combination treatment led to significant reduction in the protein expression of AR, AR-V7, EZH2, SUZ12, EED, p-Akt (Ser473) and AR regulated genes in cancer cell lines, compared to individual treatments. Co-targeting AR and EZH2 potentiated autophagy cell death in both cancer cell lines.
CONCLUSIONS: Dual targeting of AR and EZH2 with ENZU and GSK126 exhibited synergistic inhibition of AR-dependent and genespecific EZH2-mediated expression of CRPC potentiating cell death thus opening avenues simultaneously targeting EZH2 and AR in CRPC. CONCLUSIONS: VERU-111, a next generation, orally a and b tubulin inhibitor, has significant anti-tumor activity against PCa and other tumors. In the human PCa model 22Rv1, VERU-111 had a statistically significant reduction in tumor growth and was well tolerated. In contrast, IP docetaxel did not significantly reduce tumor growth and had greater toxicity. A phase 1/2 trial evaluating VERU-111 in men with metastatic castration and novel androgen blocking agent (abiraterone or enzalutamide) resistant prostate cancer is in progress. 
